Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17110335
Margolis SS, et al. (2006) Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell 127, 759-73 17110335
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T130-p - CDC25C (human)
Modsite: PAQLLCStPNGLDRG SwissProt Entrez-Gene
Orthologous residues
CDC25C (human): T130‑p, CDC25C iso3 (human): T87‑p, CDC25C (mouse): T129‑p, CDC25C (frog): T138‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), HCT116 (intestinal), HeLa (cervical), oocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  frog, human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase

S60-p - PPP2R5D (human)
Modsite: PsSNKRPsNstPPPt SwissProt Entrez-Gene
Orthologous residues
PPP2R5D (human): S60‑p, PPP2R5D (mouse): S53‑p, PPP2R5D (rat): S80‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), HCT116 (intestinal), HeLa (cervical), oocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  frog, human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Chk1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) siRNA inhibition of enzyme, phospho-antibody
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation
Effect of modification (process):  cell cycle regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PPP2CA (human) Induces pull-down assay
Comments:  enhances dephosphorylation of Cdc25C

T138-p - CDC25C (frog)
Modsite: LPRLLCStPSFKKTS SwissProt Entrez-Gene
Orthologous residues
CDC25C (human): T130‑p, CDC25C iso3 (human): T87‑p, CDC25C (mouse): T129‑p, CDC25C (frog): T138‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), HCT116 (intestinal), HeLa (cervical), oocyte
Cellular systems studied:  cell lines, primary cells
Species studied:  frog, human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK2 (human)
PHOSPHATASE PPP2CA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, immunodepletion of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic_acid increase